Damora Therapeutics, Inc. quarterly report, Q1 FY2024

Filing Overview

Registrant: Galecto, Inc. (the request metadata identifies Damora Therapeutics, Inc.; the supplied Form 10-Q is for Galecto, Inc., Nasdaq: GLTO).

Reporting period: Three months ended March 31, 2024; filed April 29, 2024. The financial statements are unaudited and prepared under U.S. GAAP.

Galecto is a clinical-stage biotechnology company developing small-molecule inhibitors targeting galectin-3 and LOXL2 for fibrotic diseases and cancer. Its remaining product candidates, GB1211 and GB2064, are in Phase 2 development. The company has no approved products and has generated no product revenue.

Financial Results and Position

MetricQ1 2024Q1 2023Change
Revenue$0$0No product revenue
Research and development expense$2.5 million$10.4 millionDown 76.2%
General and administrative expense$3.3 million$3.1 millionUp 4.7%
Total operating expenses$5.7 million$13.5 millionDown 57.4%
Other income, net$0.3 million$0.5 millionDown $0.2 million
Net loss$5.5 million$13.0 millionLoss decreased 57.8%
Net loss per share$0.20$0.51Improved
Cash used in operating activities$5.9 million$9.1 millionUse decreased $3.2 million

Other comprehensive loss was $54,000 in Q1 2024, producing total comprehensive loss of $5.5 million. Stock-based compensation was $1.4 million, or approximately 24% of total operating expenses.

At March 31, 2024, cash and cash equivalents were $21.1 million, marketable securities were $6.1 million, and total cash, cash equivalents and marketable securities were $27.2 million, compared with $33.2 million at December 31, 2023. Total assets were $32.5 million, current liabilities were $4.3 million, and stockholders’ equity was $28.2 million. The filing reports no debt financing outstanding; lease liabilities totaled approximately $155,000.

Cash used in operating activities was partially offset by $5.7 million of proceeds from sales of marketable securities. There were no financing proceeds in Q1 2024. The company had an accumulated deficit of $261.6 million at March 31, 2024.

Material Changes Versus the Prior Comparable Period

  • Research and development expense declined by $7.9 million, primarily because of discontinued clinical activities, lower chemistry, manufacturing and control costs, reduced personnel costs, and lower consulting costs.
  • The majority of Q1 2024 clinical spending was directed toward GB2064; Q1 2023 spending was primarily directed toward GB0139.
  • The company’s September 2023 restructuring reduced its workforce by approximately 70% and substantially reduced planned clinical and operating activity. The company expects the restructuring to reduce future expenses.
  • General and administrative expense increased modestly because of higher legal costs, partly offset by lower personnel costs.
  • Cash, cash equivalents and marketable securities declined by approximately $6.0 million from December 31, 2023, principally reflecting operating cash use and the timing of marketable-security sales.
  • The company incurred no ATM program sales during Q1 2024, compared with $23,000 of net proceeds in Q1 2023.
  • In January 2024, the company granted 855,000 restricted stock units; 820,000 remained outstanding at March 31, 2024. Outstanding stock options totaled approximately 6.0 million.

Guidance, Outlook, Risks and Unusual Items

Management expects expenses to decrease in the near term because of reduced clinical development and the workforce reduction, although legal, accounting, advisory and other costs related to the strategic review may offset some savings. The company expects to continue incurring net losses and does not expect product revenue unless and until a product receives regulatory approval.

The company is conducting a broad review of strategic alternatives, including an acquisition, merger, business combination, liquidation, dissolution, licensing transaction or asset sale. No timetable has been established, the board has not approved a definitive course of action, and management cannot assure that any transaction will be pursued or completed on favorable terms, or at all.

Based on current estimates, management believes the $27.2 million of cash, cash equivalents and marketable securities at March 31, 2024 will fund operating and capital requirements through at least the next twelve months from the filing date. This estimate excludes funding needs for a potential strategic transaction and may prove inaccurate. The company has no committed external source of funds other than potential ATM sales, which are subject to regulatory limitations.

On March 26, 2024, Nasdaq granted the company an additional 180-day period, through September 23, 2024, to regain compliance with the $1.00 minimum bid-price requirement. The company indicated that it may effect a reverse stock split if necessary. Failure to regain compliance could result in delisting and impair access to capital or strategic transactions.

Restructuring charges totaled approximately $3.4 million through December 31, 2023, with $485,000 of related accrued costs remaining at March 31, 2024. The company also accrued approximately $500,000 under a retention program during Q1 2024. No material legal proceedings or subsequent events requiring disclosure were reported.

Principal risks include clinical and regulatory failure, inability to secure additional financing, unfavorable or unsuccessful strategic transactions, possible Nasdaq delisting, dependence on key personnel and third-party providers, intellectual-property risks, competition, supply-chain disruption, and geopolitical and economic volatility.

Investor Verification Items

  • Verify the registrant identity: the supplied filing is for Galecto, Inc., not Damora Therapeutics, Inc.
  • Verify the remaining cash runway assumptions, particularly the exclusion of potential strategic-transaction costs and the absence of committed external funding.
  • Monitor the strategic-alternatives process for a definitive transaction, asset sale, licensing arrangement, liquidation or distribution to stockholders.
  • Monitor Nasdaq compliance and whether a reverse stock split or other action is required before September 23, 2024.
  • Assess the status, funding and clinical data for GB1211 and GB2064 after the company discontinued or reduced other development activities.
  • Track dilution from the approximately 6.0 million outstanding options, 820,000 RSUs and any future ATM or other equity financing.
  • Review future restructuring, retention, legal, accounting and advisory costs, which may accelerate cash use despite lower research spending.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.